poisar

Stocks · News reference

Kalaris Therapeutics To Present Additional Data From Phase 1a Single Ascending Dose Trial Of TH103 In Neovascular Age-Related Macular Degeneration At ASRS Annual Meeting; On Track To Share Initial Data From Phase 1b/2 Study In H1 Of 2027

Benzinga Newsdesk

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohortsEnrollment in the Phase 1b/2 multiple-ascending dose trial of TH103

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

KLRS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

    Kalaris Therapeutics (Nasdaq: KLRS), a clinical-stage biopharmaceutical company, announced that management will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company is developing TH103, a dual-action anti-VEGF therapeutic, currently in Phase 1b/2 trials for neovascular Age-related Macular Degeneration (nAMD), with preliminary data expected in the first half of 2027.

    KLRS
  3. Benzinga Newsdesk

    Kalaris Therapeutics Q2 EPS $(0.48) Beats $(0.49) Estimate

    Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 21.31 percent increase over losses of $(0.61) per share

    KLRS
  4. Abbott Cooper Pllc

    SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders

    Abbott Cooper PLLC is investigating potential fiduciary duty breaches by the board of directors of Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.). The investigation targets stockholders who continuously held shares since prior to August 19, 2025. Similar investigations are also underway for Kalaris Therapeutics (formerly AlloVir) and Abundia Global Impact Group (formerly Houston American Energy Corp.).

    SDEVKLRSAGIG